Strides Pharma Science has informed that India Ratings and Research (Ind-Ra) through its letter dated January 21, 2021 has upgraded company’s Long-Term Issuer Rating to ‘IND A+’ with a Stable Outlook from ‘IND A’ previously.
The above information is a part of company’s filings submitted to BSE.